14596 Federal Register / Vol. 72, No.
59 / Wednesday, March 28, 2007 / Notices
Dated: March 20, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–1505 Filed 3–27–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel,
Development of Immunotherapeutic Products
for the Treatment of Methamphetamine,
Addiction.
Date: April 18, 2007.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Mark Swieter, PhD, Chief,
Training and Special Projects Review Branch,
Office of Extramural Affairs, National
Institute on Drug Abuse, NIH, DHHS, 6101
Executive Boulevard, Suite 220, Bethesda,
MD 20892–8401, (301) 435–1389,
ms80x@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: March 20, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
sroberts on PROD1PC70 with NOTICES
[FR Doc. 07–1506 Filed 3–27–07; 8:45 am]
BILLING CODE 4140–01–M
VerDate Aug<31>2005 17:09 Mar 27, 2007 Jkt 211001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel, Aneurysm Study.
Date: April 5–6, 2007.
Time: 7:30 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Chicago O’Hare Airport,
O’Hare International Airport, Terminal #2,
Chicago, IL 60666.
Contact Person: Katherine Woodbury, PhD,
Scientific Review Administrator, Scientific
Review Branch, NINDS/NIH/DHHS,
Neuroscience Center, 6001 Executive Blvd,
Suite 3208, MSC 9529, Bethesda, MD 20892–
9529, (301) 496–5980, kw47o@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel, Autism, and Sleep.
Date: April 16, 2007.
Time: 10 a.m. to 12 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Katherine Woodbury, PhD,
Scientific Review Administrator, Scientific
Review Branch, NINDS/NIH/DHHS,
Neuroscience Center, 6001 Executive Blvd,
Suite 3208, MSC 9529, Bethesda, MD 20892–
9529, (301) 496–5980, kw47o@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
PO 00000 Frm 00082 Fmt 4703 Sfmt 4703 E:\FR\FM\28MRN1.SGM
Dated: March 20, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–1507 Filed 3–27–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Minority Programs
Review Committee, MBRS Review
Subcommittee B.
Date: April 3, 2007.
Time: 2 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, 45 Center Drive, Room
3AN–38, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Lisa A Dunbar, PhD, Office
of Scientific Review, National Institute of
General Medical Sciences, National Institutes
of Health, 45 Center Drive, Room 3AN12,
Bethesda, MD 20892, 301–594–2849,
dunbarl@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel, Minority Biomedical Research
Support.
Date: April 4, 2007.
Time: 3 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, 45 Center Drive, Room
3AN–18, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Rebecca H. Johnson, PhD,
Office of Scientific Review, National Institute
of General Medical Sciences, National
Institutes of Health, Natcher Building, Room
3AN18, Bethesda, MD 20892, 301–594–2771,
johnsonrh@nigms.nih.gov.
28MRN1
 Federal Register / Vol. 72, No. 59 / Wednesday, March 28, 2007 / Notices
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives, National
Institutes of Health, HHS)
Dated: March 20, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–1509 Filed 3–27–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel, ZEB1 OSR–C (A1) S
(LRP).
Date: May 18, 2007.
Time: 2 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Suite 220 small conference room,
Bethesda, MD 20892, (Telephone Conference
Call).
sroberts on PROD1PC70 with NOTICES
Contact Person: Prabha L. Atreya, PhD,
Scientific Review Administrator, Office of
Scientific Review, National Institute of
Biomedical Imaging and Bioengineering,
Bethesda, MD 20892; (301) 496–8633,
atreyapr@mail.nih.gov.
VerDate Aug<31>2005 17:09 Mar 27, 2007 Jkt 211001
Dated: May 20, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–1510 Filed 3–27–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
National Commission on Digestive
Diseases.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: National Commission
on Digestive Diseases.
Date: June 18–19, 2007.
Time: 9 a.m. to 12 p.m.
Agenda: Introductions; updates from
Working Groups; Commission timeline and
next steps; and general discussion. Pre-
registration is required. Instructions will be
available on the Commission’s Web site at
http://NCDD.niddk.nih.gov.
Place: Sheraton Crystal City, 1800 Jefferson
Davis Highway (Rt. 1), Grand Ballroom C,
Arlington, VA 22202.
Contact Person: Stephen P James, MD,
Director, Division of Digestive Diseases &
Nutrition, National Institute of Diabetes and
Digestive and Kidney Diseases, NIH, 6707
Democracy Blvd., Rm 677, Bethesda, MD
20892–5450, 301–594–7680,
natlcommdd@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: March 21, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–1512 Filed 3–27–07; 8:45 am]
BILLING CODE 4140–01–M
PO 00000 Frm 00083 Fmt 4703 Sfmt 4703 E:\FR\FM\28MRN1.SGM
14597
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
National Advisory Council on Drug
Abuse.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need assistance, such as sign language
interpretation or other reasonable
accommodations, should notify the
Contact Person listed below in advance
of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council on Drug Abuse.
Date: May 15–16, 2007.
Closed: May 15, 2007, 3 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852.
Open: May 16, 2007, 8:30 a.m. to 1 p.m.
Agenda: This portion of the meeting will
be open to the public for announcements and
reports of administrative, legislative and
program developments in the drug abuse
field.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852.
Contact Person: Teresa Levitin, PhD,
Director, Office of Extramural Affairs,
National Institute on Drug Abuse, NIH,
DHHS, Room 220, MSC 8401, 6101 Executive
Boulevard, Bethesda, MD 20892–8401, (301)
443–2755.
Any member of the public interested in
presenting oral comments to the committee
may notify the Contact Person listed on this
notice at least 10 days in advance of the
meeting. Interested individuals and
representatives of organizations may submit
a letter of intent, a brief description of the
organization represented, and a short
description of the oral presentation. Only one
representative of an organization may be
allowed to present oral comments and if
accepted by the committee, presentations
may be limited to five minutes. Both printed
28MRN1